FIM
IBRX icon

Freedom Investment Management’s ImmunityBio IBRX Stock Holding History

Freedom Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,201
Closed -$40.1K – 394
2025
Q2 		$40.1K Buy
15,201
+1,551
+11% +$4.17K ﹤0.01% 724
2025
Q1 		$41.1K Buy
+13,650
New +$41.4K ﹤0.01% 728
2024
Q2 		– Sell
-10,023
Closed -$53.8K – 828
2024
Q1 		$53.8K Sell
10,023
-1,160
-10% -$5.25K ﹤0.01% 773
2023
Q4 		$56.1K Sell
11,183
-226
-2% -$709 ﹤0.01% 736
2023
Q3 		$19.3K Buy
+11,409
New +$22.9K ﹤0.01% 667

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Freedom Investment Management's IBRX Position: Q3 2025 in Review

Freedom Investment Management sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 15,201 shares — an estimated $40.1K sold.

Freedom Investment Management first reported a position in IBRX in Q3 2023 and held it in 5 quarters. The position peaked at $56.1K in Q4 2023. 264 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

  • Freedom Investment Management reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
  • Freedom Investment Management sold 15,201 ImmunityBio shares in Q3 2025, an estimated $40.1K.
  • Freedom Investment Management first reported a position in ImmunityBio in Q3 2023 and held it in 5 quarters.
  • Freedom Investment Management's ImmunityBio position peaked at $56.1K in Q4 2023.
  • 264 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on Freedom Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.